Carbetocin Administration for the Prevention of Postpartum Hemorrhage in Twin Deliveries: A Randomized Controlled Trial

What this Trial Is About

Researchers are evaluating whether the drug carbetocin works better than the standard treatment oxytocin to prevent heavy bleeding after childbirth in people carrying twin pregnancies. Heavy bleeding, known as postpartum hemorrhage, is more common after twin births and can cause serious health problems like anemia and the need for blood transfusions. This study focuses on comparing carbetocin and oxytocin in twin deliveries to see which better reduces blood loss and to assess carbetocin's safety and practicality in this group. Participants will be randomly assigned to one of two groups: one receiving a single intravenous dose of carbetocin, and the other receiving standard intravenous oxytocin according to hospital protocol. Both treatments are given immediately after the delivery of the second twin, whether by vaginal or cesarean delivery. This is a single-center randomized controlled trial including people aged 18 years or older with twin pregnancies at or beyond 23 weeks gestation. During the study, blood tests will be done before delivery and on the day after delivery to measure hemoglobin levels as an indicator of blood loss. Participants will be monitored throughout their hospital stay and for up to six weeks afterward to assess safety and maternal outcomes. Researchers will track various outcomes including estimated blood loss, need for additional treatments, infections, intensive care admission, length of hospital stay, and breastfeeding at six weeks postpartum.

Carbetocin Uterotonic Treatment in Twin Pregnancies for Prevention of Postpartum Hemorrhage